HighTower Advisors
NVIV

HighTower Advisors’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

HighTower Advisors’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1
Closed -$57K – 2410
2017
Q2 		$57K Hold
1
– – ﹤0.01% 2022
2017
Q1 		$86K Hold
1
– – ﹤0.01% 1885
2016
Q4 		$88K Hold
1
– – ﹤0.01% 1788
2016
Q3 		$144K Hold
1
– – ﹤0.01% 1697
2016
Q2 		$135K Hold
1
– – ﹤0.01% 1573
2016
Q1 		$164K Buy
+1
New +$107K ﹤0.01% 1842

Other funds holding NVIV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $7.73B AUM 14.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

HighTower Advisors's NVIV Position: Q3 2017 in Review

HighTower Advisors sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q3 2017, closing a stake of 1 share — an estimated $57K sold.

HighTower Advisors first reported a position in NVIV in Q1 2016 and held it in 6 quarters. The position peaked at $164K in Q1 2016. 33 funds tracked by Wall St. Rank hold NVIV as of Q3 2017.

  • HighTower Advisors reported no remaining InVivo Therapeutics Holdings Corp position as of Q3 2017 after selling out during the quarter.
  • HighTower Advisors sold 1 InVivo Therapeutics Holdings Corp share in Q3 2017, an estimated $57K.
  • HighTower Advisors first reported a position in InVivo Therapeutics Holdings Corp in Q1 2016 and held it in 6 quarters.
  • HighTower Advisors's InVivo Therapeutics Holdings Corp position peaked at $164K in Q1 2016.
  • 33 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q3 2017.

Based on HighTower Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.